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aBstraCt
introduCtion. The aim of this study is the assessment of the clinical parameters related to metamorphopsia using 
M-charts and traditional Amsler tests in patients with central serous chorioretinopathy (CSCR). 
MateriaLs and Methods. Seventeen eyes of 17 patients were examined with M-charts and Amsler tests, as well 
as with ocular coherence tomography (OCT) at each of three visits during four months of follow-up. The rate of 
metamorphopsia detection was 82% with M-charts and 76% with Amsler test. 
resuLts. The vertical metamorphopsia score decreased after four months in nine patients (52.9%), 0.1° on aver-
age; increased in two patients (11.8%), mean 0.2°; and there was no change in six patients (35.3%). The horizontal 
metamorphopsia score decreased in seven patients (41.2%), 0.2° on average, increased in three patients (17.6%), 
0.23° on average, and there was no change in seven patients (41.2%). 
ConCLusions. M-charts are superior to the traditional Amsler charts in the monitoring of metamorphopsia in 
patients with CSCR. M-charts are a good diagnostic tool for quantitative assessment of metamorphopsia and mon-
itoring over time in patients with CSCR.
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introduCtion
Central serous chorioretinopathy (CSCR) is 
characterised by localised and limited serous detach-
ments of the neurosensory retina associated with 
leakage at the level of the retinal pigment epitheli-
um (RPE). The term “central” refers to the form of 
the disease causing visual symptoms due to the pres-
ence of serous detachments in the macular area [1]. 
The symptoms of the visual loss in this disease in-
clude metamorphopsia, micropsia, dyschromatop-
sia, scotoma, and reduced contrast sensitivity [2]. 
In most of the patients CSCR is a benign and 
self-limiting disease with spontaneous resolution of 
serous retinal detachment (SRD) and recovery of 
good vision. However, in some patients visual acuity 
can be worse even after retinal reattachment [1]. 
Asymptomatic subjects may have presented one or 
multiple episodes of extra macular serous detach-
ments, as often observed in the contralateral eye of 
an active CSCR patient [3].
The exact molecular mechanisms of CSCR have 
remained uncertain. Several risk factors for the de-
velopment of CSCR exist, but only high serum 
glucocorticoid and serum catecholamine levels have 
been related to the occurrence of CSCR [4, 5]. Fur-
ther risk factors that have been proposed include 
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pregnancy, alcohol consumption, untreated hyper-
tension, use of antibiotics, bone marrow or organ 
transplantation, infection of the respiratory tract, 
and infection with Helicobacter pylori [4, 6].
Metamorphopsia is a major sign in patients with 
macular diseases and is defined as a deformation of 
seen straight lines due to the displacement of photo-
receptors. Metamorphopsia is a major visual symp-
tom in patients with CSCR and often leads to poor 
visual quality, even after recovery to a good visual 
acuity. Several tools have been developed for quan-
tification of metamorphopsia, including preferential 
hyperacuity perimetry (PHP) and the Amsler test [7]. 
The M-chart is a diagnostic tool developed by Mat-
sumoto [8] to quantify the degree of metamorphop-
sia in patients with macular diseases.
The aim of this study was to determine the clin-
ical parameters related to metamorphopsia in pa-
tients with non-treated CSCR.
Methods
This prospective study was conducted in the med-
ical retina out-patents clinic of the Department of 
General Ophthalmology of the Medical University in 
Lublin, Poland. Informed consent was obtained from 
all of the subjects. We examined 17 eyes of 17 patients 
(15 men and 2 women) diagnosed with CSCR dur-
ing three separate visits: after episode of CSCR (1st 
visit), after one month (2nd visit) and three months 
(3rd visit). Each patient had a documented episode 
of CSCR confirmed by fluorescein angiography (FA) 
(HRA, Heidelberg Engineering, Germany) and op-
tical coherence tomography (OCT) (Cirrus, Zeiss, 
US). We excluded patients with the following reti-
nal diseases: age-related macular degeneration, idio - 
pathic choroidal neovascularisation (CNV), epiret-
inal membrane (ERM), vitreoretinal traction, and 
intraocular inflammation. Additionally, we excluded 
patients taking any systemic corticosteroids. 
Each patient had full ophthalmic examination 
including measurement of the best-corrected visual 
acuity (BCVA), slit-lamp biomicroscopy, fundus 
examination after dilatation, Amsler test, M-charts, 
and OCT including central retinal thickness (CRT). 
The M-charts (Inami Co., Tokyo, Japan), consist 
of 19 dotted (dot size is 0.1°) lines with dot intervals 
ranging from 0.2° to 2.0° of visual angle [9]. The 
examination is performed at a distance of 30 cm 
with appropriate near correction. At first, a vertical 
straight line (0°) on the first page of M-charts is 
shown to the patient. If the patients recognise the 
straight line as straight, the metamorphopsia score 
is 0. If a patient recognises the straight line as an 
irregular or curved line, more coarse dotted lines are 
shown to the patient in the following test. When the 
patient recognises a dotted line as straight, its visual 
angle is considered as his/her metamorphopsia score 
— a minimum visual angle of a dotted line needed 
to detect metamorphopsia [10]. Next, the M-charts 
are rotated by 90° and the same test is performed 
using horizontal lines. In this study the M-chart 
test was performed both with horizontal (MH) and 
vertical (MV) lines to obtain separate MH and MV 
M-charts scores. The M-chart result was consid-
ered positive if the metamorphopsia score was more 
than 0° (0.2–2.0°). If it was 0°, it was considered as 
negative. This assessment was done in regard to VH 
and MH separately and for both methods together 
— it was considered as positive if one of them was 
positive, and negative if both were negative [9, 11]. 
The Amsler test was positive if any blurred, wavy, or 
broken lines were reported by the patient. The OCT 
result was positive if a subretinal fluid was detected. 
resuLts
There were 15 men (88.2%) and 2 women 
(11.8%) in the study group. The mean age was 
40.4 years (range 24–53 years). The mean age of 
men was 41 and of women was 36 years. The rate 
of detection of the metamorphopsia (percentage of 
positive results) of MV was 76.5% on the first visit 
and 52.9% on the third visit, MH — 70.6% and 
47.1%, respectively, both together — 73.6% and 
50%; the sensitivity of M-charts was 82% . The 
MV score decreased after four months in nine pa-
tients (52,9%), 0.1° on average; it increased in two 
patients (11.8%), mean 0.2°; there was no change 
in six patients (35.3%). The MH score decreased in 
seven patients (41.2%), 0.2° on average, increased 
in three patients (17.6%), 0.23° on average, and 
there was no change in seven patients (41.2%). The 
median of the MV score was 0.38° (range 0–2.0°). 
The median of the MH score was 0.34° (range 
0–2.0°). The Amsler grid results improved in six 
patients, deteriorated in two patients, and remained 
the same in nine patients. The sensitivity of Amsler 
test was 76%. The mean BCVA improved from 
0.65 on the first visit to 0.78 on the third visit. 
The visual acuity in the near Snellen test improved 
from 1.0 to 0.71. The median CRT in OCT was 
380.1 μm on the first visit and 290.2 μm on the 
third visit. CRT improved in 13 patients.
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disCussion
CSCR is a major cause of vision threat among 
middle-aged men. A large number of single studies 
suggest that men are more often affected than women, 
presenting male-to-female ratios of up to 8:1 [4]. The 
mean age of patients with the acute form of this disease 
has a peak at around 40–45 years but in patients with 
chronic CSCR the mean age is higher [4, 13]. The 
clinical diagnosis in older patients is more difficult 
because chronic CSCR often resembles age-related 
macular degeneration (AMD) or can be complicated 
by choroidal neovascularisation (CNV) [1, 13, 14].
Metamorphopsia is a significant symptom of 
CSCR. M-charts may be used as a diagnostic tool in 
the detection of metamorphopsia in CSCR patients, 
it is possible to monitor quantitatively the changes in 
the degree of metamorphopsia over time. Matsumoto 
et al. [8] reported that the dotted lines of M-charts 
are designed to evaluate the fixation area because 
metamorphopsia can be noticed in the fixation area. 
The median of the MV score decreased from 0.45° to 
0.22° from first to third visit and the median of the 
MH score decreased from 0.44° to 0.31°. 
The Amsler grid, consisting of evenly spaced 
horizontal and vertical lines, has been widely used 
since 1947 to test metamorphopsia [15]. The 
Amsler grid can help detect one of the first signs 
of retinal disease as wavy, broken, or distorted lines 
or a blurred or missing area of vision. It is very 
cheap and easily understood by the patient. How-
ever, it also produces high false negative rates and 
does not allow for the quantification of the sever-
ity of metamorphopsia [9]. OCT is an accurate 
tool for qualitative and quantitative assessment of 
the macular structure. This device might show the 
precise structural changes of the macular region, 
like pigment epithelial detachment (PED), retinal 
pigment epithelium (RPE) irregularities, subretinal 
fluid, and CRT — distance between the anterior 
(internal limiting membrane) and posterior (retinal 
pigment epithelium) highly reflected boundaries 
of the retina [10]. The M-charts are superior to 
the Amsler grid in detecting metamorphopsia in 
patients with retinal disease, for example CSCR, 
AMD, or ERM. Amsler’s charts detect distortion in 
place, while M-charts uses lines to assess distortion. 
Although Amsler’s charts do not quantify the degree 
of distortion, the locations and shapes of distor-
tion can be detected. M-charts can quantify the 
degree of distortion but cannot describe the shapes 
and locations of the subject’s metamorphopsia [10]. 
The M-charts provide more information than the 
Amsler charts in regard to the horizontal and verti-
cal lines. In our study the rate of metamorphopsia 
detection in patients with CSCR was higher with 
the M-charts (82%) than with Amsler test (76%). 
Possible explanations for this high false-negative 
rate are the filling phenomenon across pathological 
scotomas and the use a preferred retinal locus away 
from the scotoma boundary [16]. Therefore, the 
Amsler grid alone does not seem to be sufficient for 
metamorphopsia detection and for monitoring the 
changes over time [9].
The rate of metamorphopsia was quantified us-
ing M-charts, and clinical parameters including ret-
inal (foveal) microstructures were monitored by the 
OCT images. Lehmann et al. [17] presented cohort 
study measurements, and 395 mm could be used 
as a sensitive value to diagnose “thick choroid” or 
“pachychoroid”. Increased choroidal thickness is as-
sociated with CSCR, but it is not mandatory for its 
diagnosis. There is a reduction in choroidal thickness 
with age, axial length, circadian rhythm, and myo-
pic refractive error, and the choroid is also thinner 
in females than in males [18]. Gotkas proved that 
affected eyes of unilateral cases were shown to have 
a greater choroidal thickness than fellow eyes [19].
In our research CRT on average decreased from 
380 μm to 290 μm, which testifies about regression 
subretinal fluid.
Fujita et al. [20] suggested that in CSCR, meta-
morphopsia results from disruption to the regular 
alignment of the photoreceptor layers followed by 
development of serous fluid. Subretinal fluid is as-
sociated with RPE leakage; other changes observed 
with OCT imaging have given insight into the 
pathogenesis of CSCR.
ConCLusions
This study showed that the rate of metamor-
phopsia detection in CSCR patients was better with 
M-charts than with Amsler grid. There is a fast and 
easy method which detect metamorphopsia when 
Amsler chart is normal. M-charts give additional in-
formation about visual function, independent of the 
visual acuity and morphological changes in OCT. 
It can be used in the quantitative assessment of the 
progression of metamorphopsia in patients suffering 
from CSCR.
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